AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory Hematologic Malignancies

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site๐Ÿ“ Shanghai Innovent Biologics (Suzhou) Co. Ltd. ยท Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tabโ€ฆ A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites๐Ÿ“ Los Alamitos๐Ÿ“ San Diego๐Ÿ“ West Hollywood Celgene ยท Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases NCT05827835Phase 1, Phase 21 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites๐Ÿ“ Chicago๐Ÿ“ Evanston๐Ÿ“ Providence AvenCell Therapeutics, Inc. ยท Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites๐Ÿ“ Denver๐Ÿ“ Atlanta๐Ÿ“ Fairway Verismo Therapeutics ยท Tests: SynKIR-310 CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site๐Ÿ“ Camden Roger Strair ยท Tests: Soursop tea CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia NCT03896269Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Liposome-encapsulated Daunorubicin-Cytarabine Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma NCT07657312Phase 21 site๐Ÿ“ Columbus Naresh Bumma ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Ascentage Pharma Group Inc. ยท Tests: APG-115, Azacitidine, Cytarabine Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma NCT04508790Phase 28 sites๐Ÿ“ Duarte๐Ÿ“ Huntington Beach๐Ÿ“ Lancaster City of Hope Medical Center ยท Tests: Dexamethasone, Leflunomide, Pomalidomide A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients NCT06508983Phase 312 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Hangzhou Sumgen Biotech Co., Ltd. ยท Tests: SG301 Injection, SG301 placebo, pomalidomide, dexamethasone Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Atlanta Andrew E. Place, MD ยท Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247EARLY Phase 11 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: JD123 injection Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS NCT06680752Phase 1, Phase 23 sites๐Ÿ“ Charlotte๐Ÿ“ Winston-Salem๐Ÿ“ Houston ARCE Therapeutics, Inc. ยท Tests: ARD103, Cyclophosphamide, Fludarabine A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites๐Ÿ“ Chandler๐Ÿ“ Duarte๐Ÿ“ Irvine Loxo Oncology, Inc. ยท Tests: Pirtobrutinib CD45BE-HSPC + CART-45 Cells NCT07451054Phase 11 site๐Ÿ“ Philadelphia University of Pennsylvania ยท Tests: CART-45 cells, CD45BE-HSPC A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites๐Ÿ“ Chicago๐Ÿ“ Rochester University of Chicago ยท Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: CAR-T A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596Phase 1, Phase 212 sites๐Ÿ“ Duarte๐Ÿ“ Denver๐Ÿ“ Tampa AstraZeneca ยท Tests: AZD4045, Daratumumab, Aldesleukin PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML NCT05105152Phase 11 site๐Ÿ“ Seattle Seattle Children's Hospital ยท Tests: SC-DARIC33 IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. NCT06713837Phase 347 sites๐Ÿ“ Brno๐Ÿ“ Hradec Krรกlovรฉ๐Ÿ“ Olomouc Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRโ€ฆ ยท Tests: High intensity therapies, Low intensity therapies Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ฮถ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) NCT03938987Phase 1, Phase 26 sites๐Ÿ“ Calgary๐Ÿ“ Calgary๐Ÿ“ Calgary University of Alberta ยท Tests: autologous CD19-directed chimeric antigen receptor (CAR) T-cells A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) NCT05927571Phase 114 sites๐Ÿ“ Camperdown๐Ÿ“ Waratah๐Ÿ“ Adelaide Genentech, Inc. ยท Tests: Cevostamab, Elranatamab, Tocilizumab A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies NCT07572006Phase 116 sites๐Ÿ“ Indianapolis๐Ÿ“ Grand Rapids๐Ÿ“ Piscataway Janssen Research & Development, LLC ยท Tests: JNJ-95804306, AML SoC, CLL/SLL SoC
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy